Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hodgkin Disease 18Lymphoma 12Urinary Bladder Neoplasms 5Melanoma 5Leukemia 2Skin Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1HIV Infections 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bladder Adenocarcinoma 1

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × Vinblastine × Clear all
NCT00885534 2015-05-06

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
7 enrolled 6 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡